Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
AstraZeneca, breast cancer and Daiichi Sankyo
US FDA approves AstraZeneca's drug for breast cancer
The U.S. Food and Drug Administration has approved AstraZeneca and partner Daiichi Sankyo's precision drug to treat a type of breast cancer, the health regulator said on Friday. The treatment, jointly developed with the Japanese company,
AstraZeneca and Daiichi Sankyo win U.S. approval for breast cancer drug
The Food and Drug Administration approved the drug for patients with advanced breast tumors whose cells bear a certain genetic signature.
FDA Approves New ADC for HR+, HER2- Breast Cancer
The US Food and Drug Administration (FDA) has approved datopotamab deruxtecan for the treatment of certain patients with unresectable or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer.
AstraZeneca Gets FDA Approval for Metastatic Breast Cancer Treatment Datroway
AstraZeneca said the U.S. Food and Drug Administration approved Datroway, a treatment for metastatic breast cancer developed in combination with Daiichi Sankyo. The Anglo-Swedish drugmaker on Friday said that the approval is for adult breast cancer patients who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.
AstraZeneca’s Datroway approved in U.S. for HER2-negative breast cancer patients
DXd, has been approved in the US for the treatment of adult patients with unresectable or metastatic hormone receptor HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.
FDA approves new MCL treatment by AstraZeneca
WILMINGTON, Del. - The U.S. Food and Drug Administration (FDA) has granted approval to AstraZeneca (NASDAQ:AZN)'s CALQUENCE® (acalabrutinib) in combination with bendamustine and rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who are ineligible for autologous hematopoietic stem cell transplantation.
20h
The Power of Personalized Breast Cancer Care
It’s a sobering statistic: 1 in 8 women in the United States will be diagnosed with breast cancer during her lifetime.1 ...
1d
Breast Cancer Rates Climb Among Younger Women
The increase in breast cancer rates among younger patients is occurring as the incidence of other early-onset cancers — ...
1d
on MSN
Women on Medicaid at Higher Risk of Breast Cancer
Breast cancer is the second leading cause of cancer death in women. Early detection results in 99% five-year survival rates.
14h
Inside Edition Reporter Undergoes Double Mastectomy After Discovering Breast Cancer on Assignment
Inside Edition' reporter Alison Hall undergoes a double mastectomy, after discovering her breast cancer while on assignment.
3d
on MSN
Danielle Fishel says she has completed radiation treatment after breast cancer diagnosis
Danielle Fishel is sharing an update about her health, saying she has completed “active cancer treatment” following her ...
2d
Huge real-world test shows AI can help identify breast cancer
Technology could soon do more than assist doctors. Thanks to advancements in cancer-identifying AI, it could actively save ...
Targeted Oncology
15h
Considering Sacituzumab in HR+, HER2- Breast Cancer After Progression
During a Case-Based Roundtable event, Laura Huppert, MD, reviewed antibody-drug conjugates for a patient with metastatic ...
3d
on MSN
Danielle Fishel opens up about breast cancer battle: 'It hurts to live right now'
"Boy Meets World" star Danielle Fishel said she is finished with radiation treatment for cancer and opened up about the side ...
Medscape
1d
Breast Cancer Screening at 40 Seems Cost-Effective in Canada
As cancer treatment costs have increased, identifying and treating early-stage cancer sooner reduces expenses and improves ...
38m
Coldstream cancer survivor talks about her journey
At just 35, Coldstream resident Meghan Kreguer faced the daunting diagnosis of aggressive Stage 3 breast cancer.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Popular topics
# Breast cancer
Related topics
AstraZeneca
Danielle Fishel
Olivia Munn
Linda Nolan
Food and Drug Administration
Feedback